-
1
-
-
84856802635
-
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
-
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-494S.
-
(2012)
Chest
, vol.141
-
-
Kearon, C.1
Akl, E.A.2
Comerota, A.J.3
-
2
-
-
34249829228
-
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
-
Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199–205
-
(2007)
Haematologica
, vol.92
, pp. 199-205
-
-
Prandoni, P.1
Noventa, F.2
Ghirarduzzi, A.3
-
3
-
-
84908205835
-
Treatment patterns of venous thromboembolism in a real-world population: The Q-VTE study cohort
-
Tagalakis V, Patenaude V, Kahn SR, et al. Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort. Thromb Res 2014; 134: 795–802
-
(2014)
Thromb Res
, vol.134
, pp. 795-802
-
-
Tagalakis, V.1
Patenaude, V.2
Kahn, S.R.3
-
4
-
-
84924869150
-
Duration of anticoagulation after venous thromboembolism in real world clinical practice
-
Ageno W, Samperiz A, Caballero R, et al. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res 2015; 135: 666–672
-
(2015)
Thromb Res
, vol.135
, pp. 666-672
-
-
Ageno, W.1
Samperiz, A.2
Caballero, R.3
-
5
-
-
84869441338
-
Low-dose aspirin for preventing recurrent venous thromboembolism
-
Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979–1987
-
(2012)
N Engl J Med
, vol.367
, pp. 1979-1987
-
-
Brighton, T.A.1
Eikelboom, J.W.2
Mann, K.3
-
6
-
-
84861402643
-
Aspirin for preventing the recurrence of venous thromboembolism
-
Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959–1967
-
(2012)
N Engl J Med
, vol.366
, pp. 1959-1967
-
-
Becattini, C.1
Agnelli, G.2
Schenone, A.3
-
7
-
-
84921536011
-
Aspirin for the prevention of recurrent venous thromboembolism: The INSPIRE collaboration
-
Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014; 130: 1062–1071
-
(2014)
Circulation
, vol.130
, pp. 1062-1071
-
-
Simes, J.1
Becattini, C.2
Agnelli, G.3
-
8
-
-
84905977363
-
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
-
Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014; 124: 1020–1028
-
(2014)
Blood
, vol.124
, pp. 1020-1028
-
-
Yeh, C.H.1
Gross, P.L.2
Weitz, J.I.3
-
9
-
-
84874003257
-
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
-
Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709–718
-
(2013)
N Engl J Med
, vol.368
, pp. 709-718
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
-
10
-
-
78650619315
-
Oral rivaroxaban for symptomatic venous thromboembolism
-
EINSTEIN Investigators
-
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510
-
(2010)
N Engl J Med
, vol.363
, pp. 2499-2510
-
-
Bauersachs, R.1
Berkowitz, S.D.2
-
11
-
-
84873596181
-
Apixaban for extended treatment of venous thromboembolism
-
Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708
-
(2013)
N Engl J Med
, vol.368
, pp. 699-708
-
-
Agnelli, G.1
Buller, H.R.2
Cohen, A.3
-
12
-
-
84859385808
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
-
EINSTEIN Investigators
-
EINSTEIN Investigators, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–1297
-
(2012)
N Engl J Med
, vol.366
, pp. 1287-1297
-
-
Buller, H.R.1
Prins, M.H.2
-
13
-
-
84884336961
-
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies
-
Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21
-
(2013)
Thromb J
, vol.11
-
-
Prins, M.H.1
Lensing, A.W.2
Bauersachs, R.3
-
14
-
-
84884874953
-
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis
-
Bamber L, Wang MY, Prins MH, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013; 110: 732–741
-
(2013)
Thromb Haemost
, vol.110
, pp. 732-741
-
-
Bamber, L.1
Wang, M.Y.2
Prins, M.H.3
-
15
-
-
84921454374
-
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial
-
Prins MH, Bamber L, Cano SJ, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015; 135: 281–288
-
(2015)
Thromb Res
, vol.135
, pp. 281-288
-
-
Prins, M.H.1
Bamber, L.2
Cano, S.J.3
-
16
-
-
65649094404
-
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement
-
Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surgery Brit Vol 2009; 91: 636–644
-
(2009)
J Bone Joint Surgery Brit Vol
, vol.91
, pp. 636-644
-
-
Eriksson, B.I.1
Kakkar, A.K.2
Turpie, A.G.3
-
17
-
-
84873514413
-
Rivaroxaban for thromboprophylaxis in acutely ill medical patients
-
Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368: 513–523
-
(2013)
N Engl J Med
, vol.368
, pp. 513-523
-
-
Cohen, A.T.1
Spiro, T.E.2
Buller, H.R.3
-
18
-
-
0029590268
-
Sample size calculation for complex clinical trials with survival endpoints
-
Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Controlled Clin Trials 1995; 16: 395–407
-
(1995)
Controlled Clin Trials
, vol.16
, pp. 395-407
-
-
Shih, J.H.1
-
19
-
-
0042031415
-
Extended Low-Intensity Anticoagulation for Thrombo-Embolism I. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism
-
Kearon C, Ginsberg JS, Kovacs MJ, et al, Extended Low-Intensity Anticoagulation for Thrombo-Embolism I. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631–699
-
(2003)
N Engl J Med
, vol.349
, pp. 631-699
-
-
Kearon, C.1
Ginsberg, J.S.2
Kovacs, M.J.3
-
20
-
-
0037431013
-
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism
-
Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425–1434.
-
(2003)
N Engl J Med
, vol.348
, pp. 1425-1434
-
-
Ridker, P.M.1
Goldhaber, S.Z.2
Danielson, E.3
|